Malinda Itchins
Overview
Explore the profile of Malinda Itchins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shahnam A, Davis A, Brown L, Sullivan I, Lin K, Ng C, et al.
Lung Cancer
. 2025 Feb;
201:108421.
PMID: 39977966
Background: KRAS G12D and G12C mutations have distinct biological traits influencing treatment response. This study examines real-world demographics, clinical characteristics, and first-line treatment outcomes in metastatic non-small-cell lung cancer (NSCLC)...
2.
3.
Itchins M, Liang S, Brown C, Barnes T, Marx G, Chin V, et al.
JTO Clin Res Rep
. 2024 Sep;
5(9):100703.
PMID: 39309618
Introduction: ALK-positive lung cancers represent a molecularly diverse disease. With drug exposure, driving selection pressure, and resistance pathways, disease relapse will emerge. There is compelling rationale to investigate novel treatment...
4.
Wilson I, Qiu M, Itchins M, Wang B, Huang M, Grimison P
Cancer Rep (Hoboken)
. 2024 Aug;
7(8):e2164.
PMID: 39188081
Background: Anaplastic lymphoma kinase (ALK) rearrangements are rare in non-myofibroblastic sarcoma and there is limited data on the efficacy of ALK tyrosine kinase inhibitors (TKIs) and mechanisms of resistance in...
5.
Narayanan S, Yuile A, Venkatesh B, McKay M, Itchins M, Pavlakis N, et al.
Br J Clin Pharmacol
. 2024 May;
90(8):1942-1951.
PMID: 38706157
Aims: Therapeutic drug monitoring (TDM) has led to significant improvements in individualized medical care, although its implementation in oncology has been limited to date. Tyrosine kinase inhibitors (TKIs) are a...
6.
Fantoni A, Warburton L, Solomon B, Alexander M, Maddula M, Brown L, et al.
Clin Lung Cancer
. 2024 May;
25(5):449-459.
PMID: 38705835
Background: Seminal trials with first-line pembrolizumab for metastatic non-small cell lung cancer (NSCLC) mandated a maximum two-years treatment. We describe real-world outcomes of a multi-site Australian cohort of patients who...
7.
Illini O, Saalfeld F, Christopoulos P, Duruisseaux M, Vikstrom A, Peled N, et al.
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612799
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed...
8.
Brown L, Khou V, Brown C, Alexander M, Jayamanne D, Wei J, et al.
Front Oncol
. 2024 Feb;
14:1305720.
PMID: 38406805
Introduction: Brain metastases commonly occur in patients with non-small cell lung cancer (NSCLC). Standard first-line treatment for NSCLC, without an EGFR, ALK or ROS1 mutation, is either chemoimmunotherapy or anti-PD-1...
9.
Alexander M, ROGERs J, Parakh S, Mitchell P, Clay T, Kao S, et al.
Intern Med J
. 2024 Feb;
54(7):1087-1096.
PMID: 38369719
Background And Aims: Lurbinectedin is a novel oncogenic transcription inhibitor active in several cancers, including small cell lung cancer (SCLC). We aimed to describe the first Australian experience of the...
10.
Venkatesh B, Yuile A, McKay M, Narayanan S, Wheeler H, Itchins M, et al.
Ther Drug Monit
. 2024 Jan;
46(3):332-343.
PMID: 38263583
Background: Osimertinib is an oral small-molecule tyrosine kinase receptor inhibitor used to treat non-small cell lung cancer (NSCLC) with a sensitizing epidermal growth factor receptor mutation. Patients may experience drug...